NASDAQ:ALLK Allakos (ALLK) Stock Forecast, Price & News $5.25 +0.25 (+5.00%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$4.98▼$5.2750-Day Range$3.60▼$5.2552-Week Range$2.54▼$8.73Volume2.77 million shsAverage Volume1.07 million shsMarket Capitalization$454.44 millionP/E RatioN/ADividend YieldN/APrice Target$13.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Allakos MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside159.0% Upside$13.60 Price TargetShort InterestHealthy8.34% of Float Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.77Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.99) to ($1.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.68 out of 5 starsMedical Sector80th out of 983 stocksPharmaceutical Preparations Industry31st out of 486 stocks 3.3 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.60, Allakos has a forecasted upside of 159.0% from its current price of $5.25.Amount of Analyst CoverageAllakos has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted8.34% of the float of Allakos has been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allakos has recently decreased by 12.58%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAllakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Allakos is -0.86. Previous Next 3.8 News and Social Media Coverage News SentimentAllakos has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Allakos this week, compared to 2 articles on an average week.Search Interest16 people have searched for ALLK on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.MarketBeat Follows5 people have added Allakos to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have not sold or bought any company stock.Percentage Held by Insiders33.25% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.07% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($1.99) to ($1.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allakos (NASDAQ:ALLK) StockAllakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.Read More Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLK Stock News HeadlinesMay 31, 2023 | benzinga.comBoard Member at Allakos Acquires Company Stock Options Worth 86,762 SharesMay 30, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Sees Significant Decline in Short InterestJune 3, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 28, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 26, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 25, 2023 | americanbankingnews.comAllakos (NASDAQ:ALLK) vs. Homology Medicines (NASDAQ:FIXX) Financial SurveyMay 16, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Sees Significant Increase in Short InterestMay 14, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Forecasted to Earn Q2 2023 Earnings of ($0.51) Per ShareJune 3, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 14, 2023 | americanbankingnews.comAllakos (NASDAQ:ALLK) Rating Increased to Buy at Jefferies Financial GroupMay 13, 2023 | finance.yahoo.comAllakos Inc. (NASDAQ:ALLK) has caught the attention of institutional investors who hold a sizeable 45% stakeMay 12, 2023 | msn.comJefferies Upgrades Allakos (ALLK)May 12, 2023 | finance.yahoo.comWhy Allakos Stock Skyrocketed Nearly 9% Higher TodayMay 12, 2023 | au.investing.comAllakos upgraded as Jefferies sees favorable setupMay 12, 2023 | msn.comAnalyst Ratings for AllakosMay 11, 2023 | msn.comAllakos: Q1 Earnings InsightsMay 10, 2023 | finanznachrichten.deAllakos Inc.: Allakos Provides Business Update and Reports First Quarter 2023 Financial ResultsMay 10, 2023 | markets.businessinsider.comLifeSci Capital Keeps Their Buy Rating on Allakos (ALLK)May 9, 2023 | finance.yahoo.comAllakos Provides Business Update and Reports First Quarter 2023 Financial ResultsApril 29, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Receives $14.75 Average PT from AnalystsApril 23, 2023 | ca.finance.yahoo.comAllakos Inc. (ALLK) Stock Historical Prices & Data - Yahoo FinanceApril 21, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Short Interest UpdateApril 4, 2023 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Receives $14.75 Consensus Price Target from BrokeragesMarch 10, 2023 | msn.comWhere Allakos Stands With AnalystsMarch 10, 2023 | msn.comWhy Allakos Stock Was Heating Up TodayMarch 6, 2023 | finance.yahoo.comAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsJanuary 26, 2023 | finance.yahoo.comIs Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic ValueSee More Headlines ALLK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLK Company Calendar Last Earnings5/09/2023Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees192Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.60 High Stock Price Forecast$22.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+159.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-319,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.12% Return on Assets-45.22% Debt Debt-to-Equity RatioN/A Current Ratio9.58 Quick Ratio9.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book1.62Miscellaneous Outstanding Shares86,560,000Free Float57,779,000Market Cap$454.44 million OptionableNot Optionable Beta0.44 Key ExecutivesRobert AlexanderChief Executive Officer & DirectorAdam L. TomasiPresidentHarlan Baird RadfordChief Financial OfficerCraig PatersonChief Medical OfficerBrad YoungbloodHead-Research & Pre-Clinical DevelopmentKey CompetitorsArbutus BiopharmaNASDAQ:ABUSEmergent BioSolutionsNYSE:EBSSIGA TechnologiesNASDAQ:SIGAErascaNASDAQ:ERASAerovate TherapeuticsNASDAQ:AVTEView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 9,765 shares on 6/1/2023Ownership: 0.038%Geode Capital Management LLCBought 27,270 shares on 5/16/2023Ownership: 0.873%Jane Street Group LLCBought 19,031 shares on 5/16/2023Ownership: 0.136%Susquehanna Fundamental Investments LLCSold 9,671 shares on 5/16/2023Ownership: 0.068%AQR Capital Management LLCBought 24,954 shares on 5/16/2023Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions ALLK Stock - Frequently Asked Questions Should I buy or sell Allakos stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLK shares. View ALLK analyst ratings or view top-rated stocks. What is Allakos' stock price forecast for 2023? 6 equities research analysts have issued 1-year target prices for Allakos' shares. Their ALLK share price forecasts range from $7.00 to $22.00. On average, they expect the company's share price to reach $13.60 in the next twelve months. This suggests a possible upside of 159.0% from the stock's current price. View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts. How have ALLK shares performed in 2023? Allakos' stock was trading at $8.42 on January 1st, 2023. Since then, ALLK stock has decreased by 37.6% and is now trading at $5.25. View the best growth stocks for 2023 here. Are investors shorting Allakos? Allakos saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 4,310,000 shares, a decrease of 12.6% from the April 30th total of 4,930,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 3.7 days. Approximately 8.3% of the shares of the stock are sold short. View Allakos' Short Interest. When is Allakos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our ALLK earnings forecast. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). What ETFs hold Allakos' stock? ETFs with the largest weight of Allakos (NASDAQ:ALLK) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA SmallCap Momentum ETF (DWAS), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ProShares Ultra Nasdaq Biotechnology (BIB), BlackRock Future Health ETF (BMED), What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS). When did Allakos IPO? (ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager. What is Allakos' stock symbol? Allakos trades on the NASDAQ under the ticker symbol "ALLK." Who are Allakos' major shareholders? Allakos' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (7.00%), Logos Global Management LP (6.40%), State Street Corp (4.42%), BlackRock Inc. (2.95%), Commodore Capital LP (2.20%) and Federated Hermes Inc. (1.76%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James. View institutional ownership trends. How do I buy shares of Allakos? Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allakos' stock price today? One share of ALLK stock can currently be purchased for approximately $5.25. How much money does Allakos make? Allakos (NASDAQ:ALLK) has a market capitalization of $454.44 million. The company earns $-319,950,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis. How many employees does Allakos have? The company employs 192 workers across the globe. How can I contact Allakos? Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com. This page (NASDAQ:ALLK) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.